The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours
about
Current Therapeutic Advances Targeting EGFR and EGFRvIII in GlioblastomaActivity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model.Recent advances on skin-resident stem/progenitor cell functions in skin regeneration, aging and cancers and novel anti-aging and cancer therapies.Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer.Regulators of homologous recombination repair as novel targets for cancer treatment.An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomasTargeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma.Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer.Targeting EGFR and PI3K pathways in ovarian cancer.Emerging treatment options in the management of non-small cell lung cancer.Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.Long-term survival outcome after postoperative recurrence of non-small-cell lung cancer: who is 'cured' from postoperative recurrence?Small Molecule T315 Promotes Casitas B-Lineage Lymphoma-Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation.The Influence of EGFR Inactivation on the Radiation Response in High Grade Glioma.
P2860
Q28087306-9B55E85D-6284-4E46-8E42-12CC0E208446Q33842810-5E4B29C9-32D3-4CC1-A9AE-D2D55DBAB9A4Q34044908-FFCAC414-E9FB-4E64-A3F6-8AFC15F31404Q34855692-88D8A95E-5D9C-4C15-8754-221DCE998955Q35200273-F9B8C453-8C0C-4C59-9976-3FC41A152743Q35623065-3A2BAA03-AAD0-4DB3-9206-9B97551A4189Q35845352-CF0EC5F9-59AE-4F3B-A906-B7E2C810F4AEQ36297064-5FD3891E-85DB-4C63-8BC6-CD51CF17020FQ36641553-56648463-5383-40F2-BA66-33DCE8D2D9A6Q36788485-4C37823B-0631-47CC-BF0C-486E172D3503Q37214329-AA63E766-62EA-45C9-98AE-8DFA68217153Q37645201-FDBC39BD-F80D-443C-A070-A4690CEE9900Q38870678-C49B011A-9FC9-4E52-8802-8E70FEF9BAE7Q47770661-8769C54B-B7AF-4EC1-B435-4B65BD35374DQ48070194-2644CDF0-CD35-4FA1-8A13-1E8FBC6EEBEEQ49703767-A6DB60B3-69C4-4197-B8AD-96ED8431D087
P2860
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The in vitro effect of gefitin ...... therapy on human solid tumours
@ast
The in vitro effect of gefitin ...... therapy on human solid tumours
@en
The in vitro effect of gefitin ...... therapy on human solid tumours
@nl
type
label
The in vitro effect of gefitin ...... therapy on human solid tumours
@ast
The in vitro effect of gefitin ...... therapy on human solid tumours
@en
The in vitro effect of gefitin ...... therapy on human solid tumours
@nl
prefLabel
The in vitro effect of gefitin ...... therapy on human solid tumours
@ast
The in vitro effect of gefitin ...... therapy on human solid tumours
@en
The in vitro effect of gefitin ...... therapy on human solid tumours
@nl
P2093
P2860
P356
P1433
P1476
The in vitro effect of gefitin ...... therapy on human solid tumours
@en
P2093
Ian A Cree
Louise A Knight
Pauline Whitehouse
Penny Johnson
Sanjay Sharma
Sharon Glaysher
Stuart Mercer
P2860
P2888
P356
10.1186/1471-2407-4-83
P407
P577
2004-11-23T00:00:00Z
P5875
P6179
1021182895